Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03397966 · ClinicalTrials.gov registry record · Phase 4
Metabolic Effects of Natriuretic Peptide Hormones
A Phase 4 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03397966: Clinical Trial Phase 4 study, sponsored by VA Office of Research and Development.
NCT03397966 is a Phase 4 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03397966, a Phase 4 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
Accumulating evidence suggests that the natriuretic peptide (NP) hormonal system has important effects on metabolism. However, more information is needed to better understand the effects of NPs on metabolism in humans. Therefore, the investigators propose a study to determine the effects of b-type natriuretic peptide (BNP) on energy and fat metabolism in humans. The investigators' primary hypothesis is that the administration of BNP will increase energy expenditure in humans. The investigators' secondary hypothesis is that BNP administration will promote changes in gene expression in fat tissue suggestive of fat "beiging" in humans. Interventions that safely increase energy expenditure and promote fat "beiging" represent potential strategies for treating metabolic dysfunction due to obesity.
Interventions
- DRUG recombinant human BNP(1-32)
- DRUG placebo (control, normal saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2019-05-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03397966
The ClinicalTrials.gov registry entry for NCT03397966 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which recombinant human BNP(1-32) is the first listed.
NCT03397966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03397966 about?
NCT03397966 is a clinical study titled "Metabolic Effects of Natriuretic Peptide Hormones". Accumulating evidence suggests that the natriuretic peptide (NP) hormonal system has important effects on metabolism. However, more information is needed to better understand the effects of NPs on metabolism in humans. Therefore, the investigators propose a study to determine the effects of b-type n...
What is the current status of trial NCT03397966?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2018-07-01. Estimated completion is 2019-05-01.
What interventions are being tested in trial NCT03397966?
The interventions under investigation include: recombinant human BNP(1-32) (DRUG), placebo (control, normal saline) (DRUG).
Who is sponsoring clinical trial NCT03397966?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.